AMRS opened at $4.10 on Tuesday. Amyris has a 52-week low of $1.87 and a 52-week high of $9.28. The company has a market cap of $313.76 million, a PE ratio of -1.62 and a beta of 1.06.
Amyris (NASDAQ:AMRS) last posted its earnings results on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.44 by ($1.51). The firm had revenue of $19.36 million during the quarter, compared to analysts’ expectations of $98.52 million. During the same quarter in the previous year, the business earned $0.61 earnings per share. The business’s revenue for the quarter was down 76.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Amyris will post -0.31 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new position in shares of Amyris during the first quarter valued at approximately $28,000. American Financial Advisors LLC purchased a new stake in Amyris in the first quarter worth $33,000. Pinnacle Wealth Management Advisory Group LLC purchased a new stake in Amyris in the first quarter worth $38,000. Jane Street Group LLC purchased a new stake in Amyris in the fourth quarter worth $48,000. Finally, HRT Financial LLC purchased a new stake in Amyris in the fourth quarter worth $52,000. 34.17% of the stock is currently owned by hedge funds and other institutional investors.
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Recommended Story: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.